Dicot Past Earnings Performance
Past criteria checks 0/6
Dicot's earnings have been declining at an average annual rate of -28.6%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been declining at an average rate of 65% per year.
Key information
-28.6%
Earnings growth rate
44.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -65.0% |
| Return on equity | -99.5% |
| Net Margin | n/a |
| Next Earnings Update | 06 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Dicot makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -44 | 45 | 0 |
| 30 Sep 23 | 0 | -37 | 37 | 0 |
| 30 Jun 23 | 0 | -34 | 34 | 0 |
| 31 Mar 23 | 0 | -32 | 32 | 0 |
| 31 Dec 22 | 0 | -32 | 32 | 0 |
| 30 Sep 22 | 0 | -32 | 31 | 0 |
| 30 Jun 22 | 0 | -31 | 31 | 0 |
| 31 Mar 22 | 0 | -28 | 28 | 0 |
| 31 Dec 21 | 0 | -27 | 27 | 0 |
| 30 Sep 21 | 0 | -23 | 23 | 0 |
| 30 Jun 21 | 0 | -22 | 22 | 0 |
| 31 Mar 21 | 0 | -19 | 19 | 0 |
| 31 Dec 20 | 0 | -18 | 18 | 0 |
| 30 Sep 20 | 1 | -17 | 26 | 0 |
| 30 Jun 20 | 1 | -16 | 23 | 0 |
| 31 Mar 20 | 1 | -16 | 17 | 0 |
| 31 Dec 19 | 1 | -13 | 14 | 0 |
| 30 Sep 19 | 0 | -12 | 4 | 0 |
| 30 Jun 19 | 0 | -10 | 5 | 0 |
| 31 Mar 19 | 0 | -10 | 10 | 0 |
| 31 Dec 18 | 0 | -6 | 7 | 0 |
| 30 Sep 18 | 0 | -6 | 7 | 0 |
| 30 Jun 18 | 0 | -4 | 5 | 0 |
| 31 Mar 18 | 0 | -2 | 3 | 0 |
| 31 Dec 17 | 0 | -2 | 2 | 0 |
| 31 Dec 16 | 0 | 0 | 0 | 0 |
Quality Earnings: DICOT is currently unprofitable.
Growing Profit Margin: DICOT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DICOT is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare DICOT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DICOT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: DICOT has a negative Return on Equity (-99.47%), as it is currently unprofitable.